Pledging
These are the original issues in this subcategory
  • TELEMARKETING FRAUD
  • ROBOCALLS
  • PHARMACEUTICAL ADS
Winning Issue » PHARMACEUTICAL ADS


For decades, the pharmaceutical industry has claimed that research costs are the reason American drugs are so expensive compared to the rest of the world. However, facts show that many of these firms spend more on advertising than on research, some more than twice as much. For several years now, Americans have been bombarded with TV ads for prescription medications. In 2018, pharmaceutical manufacturers spent nearly $6.5 billion on direct-to-consumer television, radio, online, magazine and newspaper advertising. Drug makers now market their products directly to consumers, rather than the traditional method of allowing doctors to make treatment recommendations. Pharmaceutical companies often air ads for products that treat sexual dysfunction, incontinence, pain, hormone imbalance or depression -followed by lengthy warnings of possible horrific side-effects from using their products. Some critics claim these types of ads are not appropriate to be viewed by children. They also say drug ads are not produced by people who are experts in healthcare, but who are somewhat competent in sales and marketing. Advocates say these ads should be considered for what they are, a promotion, not a source of factual consumer information. They claim most consumers are not adequately informed to assess the accuracy or truth of a drug ad, or whether it is appropriate for their condition, or if they even have a condition that requires such medication.

Proposed Legislation: H.R.4106 - Responsibility in Drug Advertising Act of 2019
Prospective Sponsor: Rep. Rosa DeLauro (CT)



Polling Options

  • I oppose reforming current pharmaceutical advertising policy and wish to donate resources to the campaign committee of Speaker Nancy Pelosi (CA).
  • I support amending the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising by: 1.) Prohibiting direct-to-consumer advertising of prescription drugs for three years after FDA approval (with a waiver possible for the final year if the FDA determines that advertising the drug would have an affirmative value for public health). 2.) Allowing the FDA to prohibit advertising for drugs that have significant adverse health effects beyond the three-year period. And wish to donate resources to the campaign committee of Rep. Rosa DeLauro (CT) and/or to an advocate group currently working with this issue.


Winning Option

  • I support amending the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising by:

    1.) Prohibiting direct-to-consumer advertising of prescription drugs for three years after FDA approval (with a waiver possible for the final year if the FDA determines that advertising the drug would have an affirmative value for public health).

    2.) Allowing the FDA to prohibit advertising for drugs that have significant adverse health effects beyond the three-year period.

    And wish to donate resources to the campaign committee of Rep. Rosa DeLauro (CT) and/or to an advocate group currently working with this issue.
You May Pledge Your Support For This Issue With A Monetary
Donation And By Writing A Letter To Your Representatives
Please login to pledge


Pledge Period - Opening Date
July 12, 2021
Pledge Period - Closing Date
July 18, 2021
Trustee Election - Begins
July 19, 2021


Suggest a Trustee for this Presentation Cycle


Suggest a worthy trustee for consideration before Day 16 of this presentation cycle. (Maximum 60 Characters)
Trustee Name